Clinical Trial Update: A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 1/2 study evaluating the combination of trastuzumab emtansine (T-DM1) with pertuzumab in HER2-positive l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pertuzumab (pertuzumab)
• Trastuzumab Emtansine (T-DM1) (trastuzumab emtansine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-07-18